Achalasia

Achalasia is a rare disorder of the esophagus that makes it difficult for food and liquid to pass into the stomach. This condition occurs when the nerves in the esophagus become damaged, causing two main problems: the lower esophageal sphincter (LES) fails to relax properly during swallowing, and the esophagus loses its normal wave-like muscle contractions (peristalsis) that push food downward. While achalasia can occur at any age, it most commonly develops between ages 30 and 60, affecting approximately 1 in 100,000 people annually. Though not curable, various treatments can effectively manage symptoms and significantly improve quality of life.

Medical Disclaimer: This information is for educational purposes only and should not replace professional medical advice. If you experience difficulty swallowing or chest pain, consult a healthcare provider promptly.

Overview

The esophagus is a muscular tube that connects the throat to the stomach, using coordinated muscle contractions to move food downward. At the junction between the esophagus and stomach lies the lower esophageal sphincter (LES), a ring of muscle that acts as a valve, opening to allow food to enter the stomach and closing to prevent stomach contents from flowing backward. In achalasia, damage to the myenteric plexus (nerve cells within the esophageal wall) disrupts this coordinated system, leading to two characteristic features: aperistalsis (absence of normal esophageal contractions) and failure of the LES to relax appropriately.

Achalasia is classified into three subtypes based on manometry findings. Type I (classic achalasia) shows minimal esophageal pressurization, Type II exhibits pan-esophageal pressurization with at least 20% of swallows, and Type III demonstrates premature or spastic contractions in at least 20% of swallows. This classification helps guide treatment decisions and predict outcomes. Type II generally has the best treatment response, while Type III can be more challenging to manage due to the spastic component.

The progressive nature of achalasia leads to gradual esophageal dilation and food stasis, which can result in complications such as aspiration pneumonia, esophagitis, and an increased risk of esophageal cancer. Early diagnosis and treatment are crucial to prevent these complications and maintain quality of life. While the exact cause remains unknown, achalasia appears to result from an autoimmune process triggered by viral infection in genetically susceptible individuals, leading to inflammation and eventual loss of inhibitory neurons in the esophageal wall.

Symptoms

The symptoms of achalasia typically develop gradually over months to years, often leading to delayed diagnosis. Patients may initially adapt their eating habits to compensate for mild symptoms, but as the condition progresses, symptoms become more pronounced and significantly impact daily life.

Primary Symptoms

  • Difficulty in swallowing (dysphagia) - the hallmark symptom
    • Initially affects solids more than liquids
    • Eventually progresses to include liquids
    • Sensation of food "sticking" in the chest
    • Need to eat slowly and drink water with meals
  • Regurgitation of undigested food
    • Often occurs hours after eating
    • Food tastes the same as when swallowed (not acidic)
    • May occur when lying down
    • Risk of aspiration, especially at night
  • Sharp chest pain or chest tightness
    • Often occurs during or after meals
    • Can be severe and mimic cardiac pain
    • May be relieved by drinking cold water
    • More common in younger patients

Associated Symptoms

  • Weight loss - often significant (10-20% of body weight)
  • Heartburn - paradoxically less common than expected
  • Cough - especially nocturnal, due to regurgitation
  • Throat feels tight - sensation of constriction
  • Hiccups - persistent or recurrent
  • Halitosis (bad breath) - from food fermentation
  • Difficulty belching - trapped air in esophagus

Compensatory Behaviors

  • Eating very slowly and chewing extensively
  • Drinking large amounts of water with meals
  • Standing or walking after eating
  • Raising arms above head to help food pass
  • Avoiding certain foods (bread, meat, raw vegetables)
  • Eating smaller, more frequent meals
  • Sleeping with head elevated

Complications and Warning Signs

  • Aspiration pneumonia - from inhaled food particles
  • Severe weight loss and malnutrition
  • Esophageal perforation (rare but serious)
  • Megaesophagus - severe dilation of esophagus
  • Increased risk of esophageal cancer (squamous cell)
  • Respiratory symptoms from aspiration

Symptom Progression

  • Early stage: Intermittent dysphagia, mainly with solids
  • Moderate stage: Consistent dysphagia, regurgitation begins
  • Advanced stage: Severe symptoms, weight loss, complications
  • End stage: Megaesophagus, sigmoid deformity, severe malnutrition

Causes

The exact cause of achalasia remains unknown, but research suggests it results from a complex interplay of genetic susceptibility, autoimmune processes, and environmental triggers. The end result is the progressive loss of inhibitory neurons in the myenteric plexus of the esophagus, leading to the characteristic features of the disease.

Primary Pathophysiology

  • Neuronal degeneration:
    • Loss of inhibitory neurons containing nitric oxide and VIP
    • Preservation of excitatory cholinergic neurons
    • Results in unopposed LES contraction
    • Progressive loss of esophageal peristalsis
  • Inflammatory infiltration:
    • T-cell lymphocytic infiltration in myenteric plexus
    • Presence of antibodies against neuronal antigens
    • Cytotoxic T-cell mediated destruction
    • Ganglionitis preceding neuronal loss

Proposed Etiologic Factors

Autoimmune Hypothesis

  • Circulating antibodies against myenteric neurons
  • Association with HLA-DQ alleles (DQA1*0103, DQB1*0603)
  • Increased prevalence of other autoimmune conditions
  • Molecular mimicry between viral and neuronal antigens
  • Female predominance suggesting autoimmune component

Viral Triggers

  • Herpes simplex virus (HSV-1):
    • HSV-1 DNA found in esophageal tissue
    • Viral proteins in myenteric neurons
    • May trigger autoimmune response
  • Other viral associations:
    • Varicella-zoster virus
    • Human papillomavirus
    • Measles virus (historical association)

Genetic Factors

  • Familial clustering (3.4% of cases)
  • Association with specific HLA alleles
  • Polymorphisms in immune response genes
  • Genetic syndromes with achalasia (Allgrove syndrome)
  • Ethnic variations in prevalence

Secondary Causes (Pseudoachalasia)

  • Malignancy:
    • Esophageal adenocarcinoma
    • Gastric cardia tumors
    • Lung cancer with mediastinal involvement
    • Paraneoplastic syndrome
  • Chagas disease:
    • Trypanosoma cruzi infection
    • Endemic in Central/South America
    • Destruction of myenteric plexus
    • Can affect entire GI tract
  • Other causes:
    • Amyloidosis
    • Sarcoidosis
    • Neurofibromatosis
    • Eosinophilic esophagitis
    • Post-fundoplication syndrome

Risk Factors

While achalasia is relatively rare and can affect anyone, certain factors may increase the likelihood of developing the condition. Understanding these risk factors helps identify individuals who may benefit from earlier evaluation and monitoring.

Demographic Factors

  • Age:
    • Peak incidence between 30-60 years
    • Can occur at any age, including children
    • Bimodal distribution in some populations
    • Later onset associated with pseudoachalasia
  • Sex:
    • Slight female predominance (1.2:1)
    • Equal distribution in some studies
    • Sex differences may vary by population
  • Ethnicity and Geography:
    • Higher rates in certain populations
    • Increased risk in areas endemic for Chagas disease
    • Possible genetic variations by ethnicity

Genetic and Familial Factors

  • Family history:
    • 2-4% have affected family members
    • Suggests genetic predisposition
    • Earlier onset in familial cases
    • Autosomal recessive pattern in some families
  • Genetic syndromes:
    • Allgrove syndrome (Triple A syndrome)
    • Down syndrome
    • Familial glucocorticoid deficiency
    • Congenital central hypoventilation syndrome
  • HLA associations:
    • HLA-DQA1*0103 and DQB1*0603
    • Increased risk with certain haplotypes
    • Suggests autoimmune component

Medical Conditions

  • Autoimmune disorders:
    • Sjögren's syndrome
    • Systemic lupus erythematosus
    • Autoimmune thyroid disease
    • Type 1 diabetes
    • Myasthenia gravis
  • Viral infections:
    • History of herpes simplex infection
    • Varicella-zoster virus
    • Previous viral esophagitis
  • Other associations:
    • Parkinson's disease
    • Hirschsprung's disease
    • Multiple endocrine neoplasia type 2B

Environmental and Lifestyle Factors

  • Geographic location:
    • Endemic areas for Chagas disease
    • Rural areas in Latin America
    • Possible environmental triggers
  • Occupational exposures:
    • Limited evidence for specific exposures
    • Some reports of clustering in certain occupations
    • Needs further research

Factors Associated with Pseudoachalasia

  • Age over 50 with new-onset symptoms
  • Rapid symptom progression (<6 months)
  • Significant weight loss (>15 kg)
  • History of malignancy
  • Difficulty passing endoscope through LES

Diagnosis

Diagnosing achalasia requires a combination of clinical evaluation and specialized testing. The average time from symptom onset to diagnosis is 4-5 years, highlighting the importance of considering achalasia in patients with persistent dysphagia. A systematic approach using multiple diagnostic modalities ensures accurate diagnosis and excludes pseudoachalasia.

Clinical Evaluation

History and Physical Examination

  • Detailed symptom history:
    • Duration and progression of dysphagia
    • Solids vs. liquids difficulty
    • Regurgitation patterns
    • Weight loss timeline
    • Chest pain characteristics
    • Compensatory behaviors
  • Red flags for pseudoachalasia:
    • Age >50 with symptoms <6 months
    • Rapid weight loss (>15 kg)
    • Difficulty passing endoscope
    • Associated constitutional symptoms
  • Physical examination:
    • Usually normal in early disease
    • Weight loss and malnutrition signs
    • Halitosis from food stasis
    • Aspiration pneumonia signs

Diagnostic Tests

High-Resolution Manometry (HRM) - Gold Standard

  • Diagnostic criteria (Chicago Classification v4.0):
    • Absent peristalsis (100% failed swallows)
    • Elevated integrated relaxation pressure (IRP) >15 mmHg
    • Not attributable to mechanical obstruction
  • Subtype classification:
    • Type I: No esophageal pressurization
    • Type II: Pan-esophageal pressurization ≥20% swallows
    • Type III: Spastic contractions ≥20% swallows

Esophagography (Barium Swallow)

  • Classic findings:
    • "Bird's beak" appearance at LES
    • Dilated esophageal body
    • Absent peristalsis
    • Delayed emptying of barium
    • Air-fluid level in upright position
  • Additional information:
    • Degree of esophageal dilation
    • Sigmoid configuration in advanced cases
    • Epiphrenic diverticulum
    • Aspiration risk assessment

Upper Endoscopy

  • Findings in achalasia:
    • Dilated esophagus with retained food/liquid
    • Resistance at gastroesophageal junction
    • "Pop" sensation when passing scope through LES
    • Normal gastric and esophageal mucosa
  • Important for:
    • Excluding mechanical obstruction
    • Ruling out pseudoachalasia
    • Evaluating for complications
    • Surveillance for dysplasia/cancer

Additional Diagnostic Tools

Functional Lumen Imaging Probe (FLIP)

  • Measures distensibility of esophagogastric junction
  • Can be performed during endoscopy
  • Useful for equivocal cases
  • Helps predict treatment response

Timed Barium Esophagram

  • Quantifies esophageal emptying
  • Useful for assessing treatment response
  • Barium column height at 1, 2, and 5 minutes
  • Normal: <2 cm at 5 minutes

CT or EUS (if pseudoachalasia suspected)

  • CT chest/abdomen for tumor evaluation
  • Endoscopic ultrasound for gastroesophageal junction
  • Evaluates wall thickness and extrinsic compression
  • Essential if red flags present

Differential Diagnosis

  • Pseudoachalasia: Malignancy, infiltrative disorders
  • Esophagogastric junction outflow obstruction: Mechanical or functional
  • Chagas disease: In endemic areas
  • Scleroderma: Absent peristalsis but low LES pressure
  • Distal esophageal spasm: Normal LES relaxation
  • Eosinophilic esophagitis: May mimic symptoms

Treatment Options

Treatment for achalasia focuses on reducing lower esophageal sphincter pressure to improve esophageal emptying and relieve symptoms. Since the condition cannot be cured, the goal is to provide long-term palliation. Treatment choice depends on patient age, comorbidities, surgical risk, local expertise, and patient preference. All current treatments are palliative, addressing the LES dysfunction rather than the underlying neuronal loss.

Surgical Treatment - Most Definitive

Laparoscopic Heller Myotomy with Fundoplication

  • Procedure details:
    • Division of circular muscle fibers of LES
    • Myotomy extends 6-8 cm on esophagus, 2-3 cm on stomach
    • Partial fundoplication (usually Dor or Toupet) to prevent reflux
    • Minimally invasive approach standard of care
  • Efficacy:
    • Success rate >90% at 5 years
    • Durable symptom relief
    • Low morbidity and mortality
    • Single treatment usually sufficient
  • Complications:
    • Esophageal perforation (1-2%)
    • Postoperative reflux (5-10% with fundoplication)
    • Dysphagia from tight fundoplication
    • Pneumothorax, bleeding (rare)

Peroral Endoscopic Myotomy (POEM)

  • Technique:
    • Endoscopic creation of submucosal tunnel
    • Myotomy performed from within tunnel
    • No anti-reflux procedure
    • Can extend myotomy length as needed
  • Advantages:
    • No external incisions
    • Excellent for Type III achalasia
    • Can tailor myotomy length
    • Shorter hospital stay
  • Considerations:
    • Higher reflux rates (40-60%)
    • Requires specialized expertise
    • Long-term data still emerging
    • May need PPI therapy

Endoscopic Treatment

Pneumatic Dilation

  • Procedure:
    • Forceful disruption of LES muscle fibers
    • Graded approach: 30mm, 35mm, 40mm balloons
    • Performed under fluoroscopy
    • May require multiple sessions
  • Efficacy:
    • Initial success 80-90%
    • 50% require repeat dilation at 5 years
    • Best for Type I and II achalasia
    • Less effective in young patients
  • Risks:
    • Perforation (2-4%)
    • Reflux (15-35%)
    • Bleeding (rare)
    • Need for repeat procedures

Botulinum Toxin Injection

  • Mechanism:
    • Inhibits acetylcholine release
    • Reduces LES pressure temporarily
    • 100 units injected in 4 quadrants
    • Effect lasts 3-6 months
  • Indications:
    • Poor surgical candidates
    • Bridge to definitive therapy
    • Patient preference
    • Diagnostic trial
  • Limitations:
    • Temporary effect
    • Decreasing efficacy with repeat injections
    • May cause submucosal fibrosis
    • Can complicate future myotomy

Medical Therapy

Limited role, mainly for patients who cannot undergo invasive treatments:

  • Calcium channel blockers:
    • Nifedipine 10-30mg sublingual before meals
    • Diltiazem 60-90mg before meals
    • Modest symptom improvement (50-70%)
    • Side effects: headache, hypotension
  • Nitrates:
    • Isosorbide dinitrate 5-10mg sublingual
    • Short-acting relief
    • Significant side effects
    • Tachyphylaxis common
  • Phosphodiesterase-5 inhibitors:
    • Sildenafil 25-50mg
    • Limited data
    • May reduce LES pressure

Treatment Algorithm

  • Good surgical candidates:
    • First choice: Laparoscopic Heller myotomy + fundoplication
    • Alternative: POEM (especially Type III)
    • Consider patient preference
  • High surgical risk:
    • Pneumatic dilation
    • Botulinum toxin if dilation contraindicated
    • Medical therapy for palliation
  • End-stage disease:
    • Esophagectomy for megaesophagus
    • Failed multiple prior treatments
    • Severe complications

Post-Treatment Management

  • PPI therapy for reflux symptoms
  • Annual symptom assessment
  • Timed barium esophagram if symptoms recur
  • Endoscopic surveillance for cancer (controversial)
  • Dietary modifications as needed
  • Monitor for treatment failure

Prevention

Primary prevention of achalasia is not possible since the exact cause remains unknown and there are no established modifiable risk factors. However, strategies focus on early detection, preventing complications, and optimizing outcomes after diagnosis.

Early Detection Strategies

  • Awareness of symptoms:
    • Education about dysphagia as warning sign
    • Distinguish from normal aging or GERD
    • Prompt evaluation of progressive symptoms
    • Don't dismiss chronic swallowing difficulties
  • High-risk populations:
    • Family members of affected individuals
    • Patients with Allgrove syndrome
    • Those with associated autoimmune conditions
    • Consider genetic counseling for familial cases

Preventing Complications

Aspiration Prevention

  • Elevate head of bed 30-45 degrees
  • Avoid eating 3-4 hours before bedtime
  • Sleep on right side to promote emptying
  • Consider sleeping in recliner if severe
  • Keep suction device bedside if needed
  • Prompt treatment of regurgitation

Nutritional Support

  • Dietary modifications:
    • Small, frequent meals
    • Liquid supplements if needed
    • Avoid foods that worsen symptoms
    • Maintain adequate hydration
    • Consider nutritionist consultation
  • Weight monitoring:
    • Regular weight checks
    • Early intervention for weight loss
    • Nutritional supplementation
    • Consider feeding tube if severe

Post-Treatment Prevention

Preventing Reflux Complications

  • Long-term PPI therapy if needed
  • Lifestyle modifications for reflux
  • Regular monitoring for esophagitis
  • Avoid foods that trigger reflux
  • Weight management
  • Smoking cessation

Cancer Surveillance

  • Increased cancer risk:
    • 16-33 fold increased risk of esophageal cancer
    • Both squamous cell and adenocarcinoma
    • Risk persists after treatment
    • Mean interval 15-20 years after diagnosis
  • Surveillance recommendations (controversial):
    • No consensus guidelines
    • Some advocate endoscopy every 3-5 years
    • Consider in long-standing disease
    • Biopsy suspicious lesions

Lifestyle Modifications

  • Eating habits:
    • Eat slowly and chew thoroughly
    • Remain upright after meals
    • Drink fluids with meals
    • Avoid carbonated beverages
    • Room temperature foods often easier
  • Stress management:
    • Stress can worsen symptoms
    • Relaxation techniques
    • Regular exercise as tolerated
    • Adequate sleep

Long-term Monitoring

  • Regular follow-up with gastroenterologist
  • Annual symptom assessment
  • Timed barium swallow if symptoms recur
  • Monitor for treatment failure
  • Address psychological impact
  • Support group participation

When to See a Doctor

Seek immediate medical attention for:

  • Severe chest pain that doesn't resolve
  • Complete inability to swallow (including saliva)
  • Signs of aspiration: coughing, choking, fever
  • Severe dehydration from inability to drink
  • Vomiting blood or black stools
  • High fever with chest symptoms

Schedule urgent appointment for:

See your doctor for:

  • Intermittent swallowing difficulties
  • Need to drink liquids to swallow solids
  • Sensation of food sticking
  • Heartburn that doesn't respond to treatment
  • Chronic cough or throat tightness
  • Family history of achalasia

Post-treatment monitoring:

  • Return of swallowing difficulties
  • New or worsening reflux symptoms
  • Weight loss despite treatment
  • Signs of complications
  • Annual follow-up appointments

Related Conditions

References

  1. Yadlapati R, Kahrilas PJ, Fox MR, et al. Esophageal motility disorders on high-resolution manometry: Chicago classification version 4.0. Neurogastroenterol Motil. 2021;33(1):e14058.
  2. Vaezi MF, Pandolfino JE, Yadlapati RH, et al. ACG Clinical Guidelines: Diagnosis and Management of Achalasia. Am J Gastroenterol. 2020;115(9):1393-1411.
  3. Zaninotto G, Bennett C, Boeckxstaens G, et al. The 2018 ISDE achalasia guidelines. Dis Esophagus. 2018;31(9):doy071.
  4. Khashab MA, Vela MF, Thosani N, et al. ASGE guideline on the management of achalasia. Gastrointest Endosc. 2020;91(2):213-227.
  5. Oude Nijhuis RAB, Zaninotto G, Roman S, et al. European guidelines on achalasia: United European Gastroenterology and European Society of Neurogastroenterology and Motility recommendations. United European Gastroenterol J. 2020;8(1):13-33.